A Phase 1 Single-Ascending Dose (SAD) and Multiple- Ascending Dose (MAD) Study of CNM-Au8 in Healthy Male and Female Volunteers
Latest Information Update: 04 Jun 2019
At a glance
- Drugs CNM Au8 (Primary)
- Indications Demyelinating disorders
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Clene Nanomedicine
- 18 Apr 2018 Status changed from recruiting to completed.
- 05 Apr 2018 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified 28 Apr 2016 )
- 06 May 2016 New trial record